Plant Name: Aristolochia triangularis
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| HTR2B; | |
| GLA; MTOR; HSD17B10; HPGD; | |
| TOP1; | |
| CHEK1; | |
| KDM4E; | |
| TP53; HIF1A; NFKB1; | |
| PMP22; HTT; GMNN; HBB; THPO; LMNA; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | GLA | Alpha-galactosidase A | P06280 | CHEMBL2524 |
| Enzyme_unclassified | MTOR | Serine/threonine-protein kinase mTOR | P42345 | CHEMBL2842 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Isomerase | TOP1 | DNA topoisomerase I | P11387 | CHEMBL1781 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Protein Kinase | CHEK1 | Serine/threonine-protein kinase Chk1 | O14757 | CHEMBL4630 |
| Small molecule receptor (family A GPCR) | HTR2B | Serotonin 2b (5-HT2b) receptor | P41595 | CHEMBL1833 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | PMP22 | Peripheral myelin protein 22 | Q01453 | CHEMBL1293298 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | GMNN | Geminin | O75496 | CHEMBL1293278 |
| Unclassified | HBB | Hemoglobin beta chain | P68871 | CHEMBL4331 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:2000377; regulation of reactive oxygen species metabolic process | 8.778E-07 | 9.557E-03 | GLA, HBB, HIF1A, MTOR, TP53 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 4.577E-05 | 4.494E-03 | TP53; HIF1A; MTOR |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.069E-04 | 4.494E-03 | TP53; NFKB1; MTOR |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.258E-04 | 4.494E-03 | TP53; NFKB1; MTOR |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.649E-04 | 4.494E-03 | HIF1A; NFKB1; MTOR |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 2.464E-04 | 5.371E-03 | TP53; HIF1A; MTOR |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 4.071E-04 | 6.526E-03 | LMNA; TP53; NFKB1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 7.002E-04 | 9.541E-03 | HIF1A; TP53; NFKB1; MTOR |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.197E-03 | 1.220E-02 | TP53; HIF1A; MTOR |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.232E-03 | 1.220E-02 | CHEK1; TP53; NFKB1 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 8.462E-04 | 1.025E-02 | HPGD; TP53; NFKB1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 4.191E-04 | 6.526E-03 | CYP1A2; CYP3A4 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.619E-03 | 1.250E-02 | NFKB1; MTOR |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 2.099E-03 | 1.250E-02 | TP53; MTOR |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.792E-03 | 1.250E-02 | HIF1A; MTOR |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 2.376E-03 | 1.250E-02 | CHEK1; TP53; NFKB1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 2.163E-03 | 1.250E-02 | TP53; NFKB1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.675E-03 | 1.250E-02 | CYP1A2; CYP3A4 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.099E-03 | 1.250E-02 | CYP1A2; CYP3A4 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 3.536E-03 | 1.526E-02 | TP53; NFKB1; MTOR |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.361E-03 | 1.250E-02 | CYP1A2; CYP3A4 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 2.638E-03 | 1.250E-02 | TP53; NFKB1 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 5.203E-03 | 1.969E-02 | TP53; NFKB1; MTOR |
| hsa04115 | p53 signaling pathway_Homo sapiens_hsa04115 | 2.361E-03 | 1.250E-02 | CHEK1; TP53 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 2.429E-03 | 1.250E-02 | NFKB1; MTOR |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.638E-03 | 1.250E-02 | CYP1A2; CYP3A4 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 4.981E-03 | 1.969E-02 | HIF1A; MTOR |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 3.639E-03 | 1.526E-02 | TP53; NFKB1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 3.315E-03 | 1.506E-02 | CYP1A2; CYP3A4 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 5.776E-03 | 2.099E-02 | NFKB1; MTOR |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 6.959E-03 | 2.370E-02 | TP53; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 6.959E-03 | 2.370E-02 | TP53; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.015E-02 | 3.073E-02 | TP53; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 8.857E-03 | 2.758E-02 | TP53; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 8.485E-03 | 2.720E-02 | TP53; NFKB1 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 7.414E-03 | 2.449E-02 | CHEK1; TP53 |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 1.180E-02 | 3.477E-02 | THPO; MTOR |
| hsa03013 | RNA transport_Homo sapiens_hsa03013 | 1.387E-02 | 3.979E-02 | SMN2; SMN1 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.879E-02 | 4.877E-02 | TP53; NFKB1 |
| hsa05016 | Huntington's disease_Homo sapiens_hsa05016 | 1.725E-02 | 4.585E-02 | HTT; TP53 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.592E-02 | 4.339E-02 | TP53; NFKB1 |
| hsa00603 | Glycosphingolipid biosynthesis - globo series_Homo sapiens_hsa00603 | 1.460E-02 | 4.082E-02 | GLA |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 5.240E-03 | 1.969E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| NA: NA | Coronary artery restenosis | NA | MTOR |
| I00-I99: Diseases of the circulatory system | Coronary heart disease | I25.1 | HTR2B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Fabry's disease | E75.2 | GLA |
| C00-D49: Neoplasms | Advanced kidney cancer | C64 | MTOR |
| C00-D49: Neoplasms | Advanced ovarian cancer | NA | TOP1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TOP1; TP53 |
| I00-I99: Diseases of the circulatory system | Congestive heart failure | I50 | HTR2B |
| C00-D49: Neoplasms | Renal cancer | C64 | MTOR |
| C00-D49: Neoplasms | Gastric cancer | C16 | TOP1 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Organ rejection | D89.8, T86 | MTOR |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MTOR |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | MTOR |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MTOR; CHEK1 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MTOR |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TOP1 |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | HTR2B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | TOP1 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TOP1; TP53 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MTOR; CHEK1; TOP1; HIF1A; TP53 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | TOP1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychoses | F20-F29 | HTR2B |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HTR2B; HIF1A |
| C00-D49: Neoplasms | Breast cancer | C50 | TOP1 |
| C00-D49: Neoplasms | Bladder cancer | C67 | MTOR; TOP1 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | MTOR |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MTOR; CHEK1; CHEK1 |
| A00-B99: Certain infectious and parasitic diseases | Acquired immune deficiency syndrome | B20 | TOP1 |
| A00-B99: Certain infectious and parasitic diseases | Dutch elm disease | B81-B83 | MTOR |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MTOR |
| C00-D49: Neoplasms | Esophageal cancer | C15 | TOP1 |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | TOP1 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | HTR2B |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | TOP1; TOP1 |
| C00-D49: Neoplasms | Solid tumors | NA | MTOR |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Beta thalassemia | D56.1 | HBB |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR2B |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | MTOR; CHEK1; HIF1A |
| C00-D49: Neoplasms | Cancer | C00-C96 | MTOR; CHEK1; TOP1; NFKB1; HIF1A; TP53 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Transplant rejection | D89.8, T86 | MTOR |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TOP1 |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | CHEK1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | MTOR; MTOR |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | TOP1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| I00-I99: Diseases of the circulatory system | Cerebral infarction | I63 | HTR2B |
| C00-D49: Neoplasms | Sarcoma | C81-C86 | MTOR |